RXST
RxSight, Inc. [RXST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RXST Stock Summary
Top RXST Correlated Resources
RXST
Top 10 Correlated ETFs
RXST
Top 10 Correlated Stocks
RXST
In the News
RxSight, Inc. (RXST) Q1 2023 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Participants Allen Gong - JP Morgan Craig Bijou - Bank of America Joseph Conway - Needham & Co. Ryan Zimmerman - BTIG Steven Lichtman - Oppenheimer Lawrence Biegelsen - Wells Fargo Operator Welcome to the RxSight First Quarter 2023 Earnings Conference Call. Please be advised that today's conference is being recorded.
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.54 per share a year ago.
RxSight, Inc. to Present at the Bank of America Healthcare Conference
ALISO VIEJO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.
RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023
ALISO VIEJO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.
RxSight, Inc. to Present at the Needham Healthcare Conference
ALISO VIEJO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Needham Healthcare Conference.
4 Best Breakout Stocks to Buy Now for Superlative Returns
CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.
How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%
The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RxSight, Inc. (RXST) Q4 2022 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Alex Huang – Investor Relations Ron Kurtz – President and Chief Executive Officer Shelley Thunen – Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Robbie Marcus – JPMorgan Ryan Zimmerman – BTIG David Saxon – Needham Operator Good day and thank you for standing by. Welcome to the RxSight Fourth Quarter Earnings Conference Call.
RxSight, Inc. to Present at the Oppenheimer Healthcare Conference
ALISO VIEJO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Oppenheimer Healthcare Conference.
RXST Financial details
RXST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue per share | 0.12 | 0.77 | 1.66 | 1.77 | |
| Net income per share | 6.72 | 1.45 | -3.57 | -2.41 | |
| Operating cash flow per share | -2.16 | -1.85 | -3.28 | -2.13 | |
| Free cash flow per share | -2.38 | -1.98 | -3.42 | -2.21 | |
| Cash per share | 4.29 | 3.62 | 11.69 | 3.82 | |
| Book value per share | -16.22 | -15.6 | 10.15 | 3.25 | |
| Tangible book value per share | -16.22 | -15.6 | 10.15 | 3.25 | |
| Share holders equity per share | -16.22 | -15.6 | 10.15 | 3.25 | |
| Interest debt per share | 0.3 | 1.64 | 3.57 | 1.81 | |
| Market cap | 300.55M | 305.17M | 153.28M | 350.48M | |
| Enterprise value | 298.1M | 321.93M | 173.85M | 383.64M | |
| P/E ratio | 2.38 | 11.07 | -3.15 | -5.25 | |
| Price to sales ratio | 134.11 | 20.79 | 6.78 | 7.15 | |
| POCF ratio | -7.4 | -8.67 | -3.43 | -5.96 | |
| PFCF ratio | -6.72 | -8.09 | -3.29 | -5.72 | |
| P/B Ratio | -0.99 | -1.03 | 1.11 | 3.9 | |
| PTB ratio | -0.99 | -1.03 | 1.11 | 3.9 | |
| EV to sales | 133.02 | 21.93 | 7.69 | 7.83 | |
| Enterprise value over EBITDA | -7.39 | -10.44 | -3.3 | -6.21 | |
| EV to operating cash flow | -7.34 | -9.14 | -3.89 | -6.52 | |
| EV to free cash flow | -6.67 | -8.53 | -3.73 | -6.26 | |
| Earnings yield | 0.42 | 0.09 | -0.32 | -0.19 | |
| Free cash flow yield | -0.15 | -0.12 | -0.3 | -0.17 | |
| Debt to equity | -1.36 | -1.34 | 0.39 | 0.67 | |
| Debt to assets | 3.76 | 3.96 | 0.28 | 0.4 | |
| Net debt to EBITDA | 0.06 | -0.54 | -0.39 | -0.54 | |
| Current ratio | 10.67 | 7.03 | 15.92 | 7.81 | |
| Interest coverage | -1.77K | -69.42 | -14.34 | -12.8 | |
| Income quality | -0.32 | -1.28 | 0.92 | 0.88 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 13.19 | 1.49 | 1.08 | 0.53 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.1 | 0.07 | 0.04 | 0.04 | |
| Capex to revenue | -1.82 | -0.17 | -0.09 | -0.05 | |
| Capex to depreciation | -1.04 | -0.63 | -0.49 | -0.59 | |
| Stock based compensation to revenue | 2.05 | 0.29 | 0.34 | 0.23 | |
| Graham number | 49.51 | 22.53 | 28.56 | 13.28 | |
| ROIC | -0.5 | -0.49 | -0.37 | -0.51 | |
| Return on tangible assets | 1.14 | 0.27 | -0.25 | -0.44 | |
| Graham Net | -17.58 | -16.93 | 8.26 | 2.21 | |
| Working capital | 81.74M | 69.9M | 165.22M | 117.32M | |
| Tangible asset value | -304.61M | -297.53M | 138.24M | 89.9M | |
| Net current asset value | -324.84M | -316.71M | 121.82M | 74.29M | |
| Invested capital | -0.02 | -0.1 | 0.33 | 0.5 | |
| Average receivables | 0 | 1.83M | 3.86M | 7.91M | |
| Average payables | 0 | 1.67M | 1.41M | 2.14M | |
| Average inventory | 0 | 7.75M | 8.16M | 11.43M | |
| Days sales outstanding | 128.51 | 71.24 | 78.55 | 81.6 | |
| Days payables outstanding | 197.69 | 31.91 | 34.11 | 34.22 | |
| Days of inventory on hand | 649 | 233.19 | 162.19 | 195.64 | |
| Receivables turnover | 2.84 | 5.12 | 4.65 | 4.47 | |
| Payables turnover | 1.85 | 11.44 | 10.7 | 10.67 | |
| Inventory turnover | 0.56 | 1.57 | 2.25 | 1.87 | |
| ROE | -0.41 | -0.09 | -0.35 | -0.74 | |
| Capex per share | -0.22 | -0.13 | -0.14 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.33 | 0.41 | 0.46 | 0.57 | 0.55 | |
| Net income per share | -0.64 | -0.64 | -0.64 | -0.56 | -0.47 | |
| Operating cash flow per share | -0.55 | -0.54 | -0.55 | -0.49 | -0.56 | |
| Free cash flow per share | -0.56 | -0.58 | -0.57 | -0.51 | -0.59 | |
| Cash per share | 5.24 | 4.67 | 4.08 | 3.78 | 4.87 | |
| Book value per share | 4.49 | 3.99 | 3.47 | 3.21 | 4.58 | |
| Tangible book value per share | 4.49 | 3.99 | 3.47 | 3.21 | 4.58 | |
| Share holders equity per share | 4.49 | 3.99 | 3.47 | 3.21 | 4.58 | |
| Interest debt per share | 1.68 | 1.69 | 1.69 | 1.66 | 1.46 | |
| Market cap | 339.53M | 388.04M | 331.99M | 354.64M | 527.71M | |
| Enterprise value | 360.3M | 409.61M | 368.41M | 387.8M | 561.32M | |
| P/E ratio | -4.82 | -5.49 | -4.69 | -5.68 | -8.89 | |
| Price to sales ratio | 37.97 | 34.16 | 26.32 | 22.04 | 30.17 | |
| POCF ratio | -22.66 | -26.18 | -21.86 | -25.6 | -29.71 | |
| PFCF ratio | -22.11 | -24.4 | -21.05 | -24.95 | -28.51 | |
| P/B Ratio | 2.76 | 3.53 | 3.46 | 3.94 | 3.64 | |
| PTB ratio | 2.76 | 3.53 | 3.46 | 3.94 | 3.64 | |
| EV to sales | 40.29 | 36.06 | 29.2 | 24.1 | 32.1 | |
| Enterprise value over EBITDA | -23.25 | -28.15 | -25.34 | -27.4 | -47.96 | |
| EV to operating cash flow | -24.04 | -27.63 | -24.26 | -27.99 | -31.6 | |
| EV to free cash flow | -23.46 | -25.76 | -23.36 | -27.28 | -30.32 | |
| Earnings yield | -0.05 | -0.05 | -0.05 | -0.04 | -0.03 | |
| Free cash flow yield | -0.05 | -0.04 | -0.05 | -0.04 | -0.04 | |
| Debt to equity | 0.44 | 0.52 | 0.62 | 0.67 | 0.4 | |
| Debt to assets | 0.3 | 0.34 | 0.38 | 0.4 | 0.28 | |
| Net debt to EBITDA | -1.34 | -1.48 | -2.5 | -2.34 | -2.87 | |
| Current ratio | 15.12 | 11.54 | 8.5 | 7.81 | 12.62 | |
| Interest coverage | -15.64 | -13.9 | -12.28 | -10.33 | -8.69 | |
| Income quality | 0.85 | 0.89 | 0.9 | 0.89 | 1.34 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.75 | 0.55 | 0.51 | 0.42 | 0.41 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.07 | 0.04 | 0.03 | 0.04 | |
| Capex to revenue | -0.04 | -0.1 | -0.05 | -0.02 | -0.04 | |
| Capex to depreciation | -0.36 | -1.03 | -0.59 | -0.38 | -0.75 | |
| Stock based compensation to revenue | 0.3 | 0.26 | 0.23 | 0.18 | 0.19 | |
| Graham number | 8.05 | 7.59 | 7.06 | 6.35 | 6.95 | |
| ROIC | -0.13 | -0.14 | -0.13 | -0.12 | -0.08 | |
| Return on tangible assets | -0.1 | -0.11 | -0.11 | -0.1 | -0.07 | |
| Graham Net | 3.59 | 3.01 | 2.44 | 2.19 | 3.63 | |
| Working capital | 150.49M | 136.93M | 122.79M | 117.32M | 172.79M | |
| Tangible asset value | 123.16M | 109.99M | 95.96M | 89.9M | 145.01M | |
| Net current asset value | 107.25M | 93.2M | 79.42M | 74.29M | 130.14M | |
| Invested capital | 0.36 | 0.41 | 0.47 | 0.5 | 0.31 | |
| Average receivables | 5.24M | 6.26M | 7.95M | 9.99M | 11.81M | |
| Average payables | 2.14M | 2.93M | 3.72M | 3.38M | 3.16M | |
| Average inventory | 8.26M | 10.06M | 13.48M | 15.09M | 16.45M | |
| Days sales outstanding | 56.62 | 54.54 | 64.35 | 61.29 | 65.19 | |
| Days payables outstanding | 44.94 | 44.88 | 51.73 | 26.95 | 46.96 | |
| Days of inventory on hand | 147.48 | 159.16 | 190.14 | 154.07 | 228.28 | |
| Receivables turnover | 1.59 | 1.65 | 1.4 | 1.47 | 1.38 | |
| Payables turnover | 2 | 2.01 | 1.74 | 3.34 | 1.92 | |
| Inventory turnover | 0.61 | 0.57 | 0.47 | 0.58 | 0.39 | |
| ROE | -0.14 | -0.16 | -0.18 | -0.17 | -0.1 | |
| Capex per share | -0.01 | -0.04 | -0.02 | -0.01 | -0.02 |
RXST Frequently Asked Questions
What is RxSight, Inc. stock symbol ?
RxSight, Inc. is a US stock , located in Aliso viejo of Ca and trading under the symbol RXST
What is RxSight, Inc. stock quote today ?
RxSight, Inc. stock price is $26.19 today.
Is RxSight, Inc. stock public?
Yes, RxSight, Inc. is a publicly traded company.
Company Profile
- Volume Average 302.64K
- Market Capitalization 884.55M
- Employee 292
- CEO Dr. Ronald M. Kurtz M.D.
- Headquarters Aliso Viejo,CA,US
- IPO Date 2021-07-30
-
Website
https://www.rxsight.com 
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
